To access any content or REGISTER in less than 3 minutes.
Register
Menu
Are you medical worker?
No, visit
Your account was deleted
Please login to MyServier to continue reading this content
or sign in without a password
No account yet?
You already have an account associated with this email address. Please log in to continue.
or sign in without a password
No account yet?

What is your treatment approach for mIDH1 AML patients?

03.09.2026
2

IVO Bridge – Episode 5
In this video, Dr. Eytan Stein presents the outcomes and treatment toxicities of Azacitidine and Venetoclax in patients with IDH mutant Acute Myeloid Leukemia (AML).

Dr. Eytan Stein – Hematologist – Oncologist – Memorial Sloan Kettering Cancer Center, New York, USA

Content exclusive for connected users. Please sign in or register to access more.

Already have an account?

New here?

Create account